Leonardo Leal-Mercado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonardo Leal-Mercado has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Sonia Roman
Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, “Fray Antonio Alcalde”, Hospital #278, Col. El Retiro, Guadalajara 44280, Jalisco, Mexico
4 shared publications - Arturo Panduro
Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, Guadalajara, Jalisco, Mexico
3 shared publications - Alexis Jose-Abrego
Departamento de Medicina Genómica en Hepatología, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara 44280, Jalisco, Mexico
2 shared publications - Claudia Ojeda-Granados
Department of Medical and Surgical Sciences and Advanced Technologies “GF Ingrassia”, University of Catania, 95123 Catania, Italy
1 shared publication - Karina Gonzalez-Aldaco
Centro Universitario de los Valles, Universidad de Guadalajara, Carretera Guadalajara-Ameca Km. 45.5, Ameca 46600, Jalisco, Mexico
1 shared publication Liliana Campos-Medina
Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
1 shared publication
Latest Publications
- Open Access
- 15 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8977
Genome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention
Viral hepatitis B and C (HBV and HCV) and metabolic dysfunction-associated steatotic liver disease (MASLD) are major public health concerns in Mexico, driving liver cirrhosis and hepatocellular carcinoma. The Genome-based Mexican (GENOMEX) diet, rich in bioactive compounds, may provide a nutritional strategy for preventing and managing liver disease. This study combines a literature review with integrative bioinformatic analyses to map the antiviral and hepatoprotective mechanisms activated by GENOMEX-derived bioactives and assess their therapeutic potential for preventing and managing liver disease. A literature-based review integrated with bioinformatics to identify the pathways activated by nutrients and bioactive compounds of the GENOMEX diet against HBV, HCV, and MASLD, incorporating data from in silico, in vitro, in vivo, and clinical studies, was conducted. An integrative bioinformatic approach, incorporating the Comparative Toxicogenomic Database and Functional Enrichment Analysis (STRING, DAVID, and Enrichr), was used to identify links between genes, nutrients, and bioactive compounds, with a subset of Mexican food staples included in the GENOMEX diet. The GENOMEX diet includes bioactive nutrients that may modulate molecular pathways related to immune response, oxidative stress, nutrient metabolism, and inflammation. Through integrative analysis, we identified key molecular targets—including TNF, PPARA, TP53, and IL6—that are implicated in viral replication, MASLD progression, and hepatocarcinogenesis. Functional enrichment revealed that these traditional Mexican foods and their nutrients are associated with genes and pathways involved in viral infection, metabolic dysfunction, fibrosis, and liver cancer. These findings highlight that the gene–nutrient interactions of the Mexican staple food in the GENOMEX diet can be integrated into nutritional strategies to prevent and manage HBV, HCV, and MASLD, while reducing fibrosis and HCC progression. These strategies are especially relevant in regions where antiviral treatments are limited due to high costs, antiviral resistance, and an escalating mismatch between the population’s evolutionary genetics and modern environment.
- 15 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8977
Open AccessGenome-Based Mexican Diet Bioactives Target Molecular Pathways in HBV, HCV, and MASLD: A Bioinformatic Approach for Liver Disease Prevention
Viral hepatitis B and C (HBV and HCV) and metabolic dysfunction-associated steatotic liver disease (MASLD) are major public health concerns in Mexico, driving liver cirrhosis and hepatocellular carcinoma. The Genome-based Mexican (GENOMEX) diet, rich in bioactive compounds, may provide a nutritional strategy for preventing and managing liver disease. This study combines a literature review with integrative bioinformatic analyses to map the antiviral and hepatoprotective mechanisms activated by GENOMEX-derived bioactives and assess their therapeutic potential for preventing and managing liver disease. A literature-based review integrated with bioinformatics to identify the pathways activated by nutrients and bioactive compounds of the GENOMEX diet against HBV, HCV, and MASLD, incorporating data from in silico, in vitro, in vivo, and clinical studies, was conducted. An integrative bioinformatic approach, incorporating the Comparative Toxicogenomic Database and Functional Enrichment Analysis (STRING, DAVID, and Enrichr), was used to identify links between genes, nutrients, and bioactive compounds, with a subset of Mexican food staples included in the GENOMEX diet. The GENOMEX diet includes bioactive nutrients that may modulate molecular pathways related to immune response, oxidative stress, nutrient metabolism, and inflammation. Through integrative analysis, we identified key molecular targets—including TNF, PPARA, TP53, and IL6—that are implicated in viral replication, MASLD progression, and hepatocarcinogenesis. Functional enrichment revealed that these traditional Mexican foods and their nutrients are associated with genes and pathways involved in viral infection, metabolic dysfunction, fibrosis, and liver cancer. These findings highlight that the gene–nutrient interactions of the Mexican staple food in the GENOMEX diet can be integrated into nutritional strategies to prevent and manage HBV, HCV, and MASLD, while reducing fibrosis and HCC progression. These strategies are especially relevant in regions where antiviral treatments are limited due to high costs, antiviral resistance, and an escalating mismatch between the population’s evolutionary genetics and modern environment.
- Open Access
- 24 November 2024
- Published by MDPI AG in Clinics and Practice
- Vol. 14 (6) , 2542-2558
Metabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management
Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely associated with obesity and other cardiometabolic risk factors. MASLD has rapidly become the most common cause of liver disease worldwide, currently affecting 38% of the global population. Excess weight causes chronic inflammation and the activation of different pathways involved in liver damage. MASLD can progress from simple steatosis to steatohepatitis, giving way to its inflammatory component, metabolic dysfunction-associated steatohepatitis (MASH), previously recognized as non-alcoholic steatosis hepatitis (NASH). Chronic hepatitis C virus (HCV) infection remains a significant challenge to liver health as it triggers hepatic inflammation, metabolic disruption, and hepatic steatosis. The convergence of MASLD and chronic HCV infection can significantly alter the course of liver disease and accelerate the progression to severe liver damage. Currently, HCV treatment has a high cure rate. However, in patients who achieve a sustained virological response after treatment with direct-acting antivirals, weight gain, and excessive calorie intake may contribute to increased liver steatosis and a higher risk of liver disease progression. Therefore, the effective clinical and nutritional management of HCV patients, both before and after viral eradication, is crucial to reducing the risk of death from hepatocellular carcinoma. Understanding the complex interactions between MASLD and HCV infection is crucial for managing these patients appropriately. Herein, host and viral mechanisms inducing liver damage during the coexistence of MASLD and HCV infection are described, and their therapeutic and dietary management are discussed.
- 24 November 2024
- Published by MDPI AG in Clinics and Practice
- Vol. 14 (6) , 2542-2558
Open AccessMetabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management
Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely associated with obesity and other cardiometabolic risk factors. MASLD has rapidly become the most common cause of liver disease worldwide, currently affecting 38% of the global population. Excess weight causes chronic inflammation and the activation of different pathways involved in liver damage. MASLD can progress from simple steatosis to steatohepatitis, giving way to its inflammatory component, metabolic dysfunction-associated steatohepatitis (MASH), previously recognized as non-alcoholic steatosis hepatitis (NASH). Chronic hepatitis C virus (HCV) infection remains a significant challenge to liver health as it triggers hepatic inflammation, metabolic disruption, and hepatic steatosis. The convergence of MASLD and chronic HCV infection can significantly alter the course of liver disease and accelerate the progression to severe liver damage. Currently, HCV treatment has a high cure rate. However, in patients who achieve a sustained virological response after treatment with direct-acting antivirals, weight gain, and excessive calorie intake may contribute to increased liver steatosis and a higher risk of liver disease progression. Therefore, the effective clinical and nutritional management of HCV patients, both before and after viral eradication, is crucial to reducing the risk of death from hepatocellular carcinoma. Understanding the complex interactions between MASLD and HCV infection is crucial for managing these patients appropriately. Herein, host and viral mechanisms inducing liver damage during the coexistence of MASLD and HCV infection are described, and their therapeutic and dietary management are discussed.
- Open Access
Risk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico
The Hepatitis C Virus (HCV), with its diverse genotypes and subtypes, has significantly impacted the health of millions of people worldwide. Analyzing the risk factors is essential to understanding the spread of the disease and developing appropriate prevention strategies. This study aimed to identify risk factors associated with HCV subtype transmission and calculate the emergence time of subtype 1a in Mexico. A cross-sectional study was conducted from January 2014 to December 2018, involving 260 HCV-infected adults. HCV infection was confirmed via Enzyme-Linked Immunosorbent Assay, and viral load was measured by real-time PCR. Genotyping/subtyping tools were the Line Probe Assay and Sanger sequencing of the non-structural region 5B (NS5B). The most frequent HCV subtype was 1a (58.5%), followed by subtypes 1b (19.2%), 3a (13.1%), 2b (5.4%), 2a/2c (2.7%), 2a (0.8%), and 4a (0.4%). Intravenous drug use and tattoos were significant risk factors for subtypes 1a and 3a, while hemodialysis and blood transfusion were linked with subtype 1b. For the evolutionary analysis, 73 high-quality DNA sequences of the HCV subtype 1a NS5B region were used, employing a Bayesian coalescent analysis approach. This analysis suggested that subtype 1a was introduced to Mexico in 1976, followed by a diversification event in the mid-1980s. An exponential increase in cases was observed from 1998 to 2006, stabilizing by 2014. In conclusion, this study found that HCV subtypes follow distinct transmission routes, emphasizing the need for targeted prevention strategies. Additionally, the findings provide valuable insights into the origin of HCV subtype 1a. By analyzing the history, risk factors, and dynamics of the HCV epidemic, we have identified these measures: limiting the harm of intravenous drug trafficking, enhancing medical training and infrastructure, and ensuring universal access to antiviral treatments. The successful implementation of these strategies could lead to an HCV-free future in Mexico.
Open AccessRisk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico
The Hepatitis C Virus (HCV), with its diverse genotypes and subtypes, has significantly impacted the health of millions of people worldwide. Analyzing the risk factors is essential to understanding the spread of the disease and developing appropriate prevention strategies. This study aimed to identify risk factors associated with HCV subtype transmission and calculate the emergence time of subtype 1a in Mexico. A cross-sectional study was conducted from January 2014 to December 2018, involving 260 HCV-infected adults. HCV infection was confirmed via Enzyme-Linked Immunosorbent Assay, and viral load was measured by real-time PCR. Genotyping/subtyping tools were the Line Probe Assay and Sanger sequencing of the non-structural region 5B (NS5B). The most frequent HCV subtype was 1a (58.5%), followed by subtypes 1b (19.2%), 3a (13.1%), 2b (5.4%), 2a/2c (2.7%), 2a (0.8%), and 4a (0.4%). Intravenous drug use and tattoos were significant risk factors for subtypes 1a and 3a, while hemodialysis and blood transfusion were linked with subtype 1b. For the evolutionary analysis, 73 high-quality DNA sequences of the HCV subtype 1a NS5B region were used, employing a Bayesian coalescent analysis approach. This analysis suggested that subtype 1a was introduced to Mexico in 1976, followed by a diversification event in the mid-1980s. An exponential increase in cases was observed from 1998 to 2006, stabilizing by 2014. In conclusion, this study found that HCV subtypes follow distinct transmission routes, emphasizing the need for targeted prevention strategies. Additionally, the findings provide valuable insights into the origin of HCV subtype 1a. By analyzing the history, risk factors, and dynamics of the HCV epidemic, we have identified these measures: limiting the harm of intravenous drug trafficking, enhancing medical training and infrastructure, and ensuring universal access to antiviral treatments. The successful implementation of these strategies could lead to an HCV-free future in Mexico.
- Open Access
- 24 May 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1370595
Personalized nutrition: the end of the one-diet-fits-all era
Personalized Nutrition emerged as a new trend for providing nutritional and food advice based on the individual’s genetic composition, a field driven by the advancements in the multi-omic sciences throughout the last century. It intends not only to tailor the recommended daily allowances of nutrients and functional foods that a person may need but also to maintain the principles of sustainability and eco-friendliness. This principle implies the implementation of strategies within the healthcare system to advocate for the ending of the one-diet-fits-all paradigm by considering a personalized diet as an ally to prevent diet-related chronic diseases. In this Perspective, we highlight the potential benefits of such a paradigm within the region of Latin America, particularly Mexico, where the genetic admixture of the population, food biodiversity, and food culture provide unique opportunities to establish personalized nutrigenetic strategies. These strategies could play a crucial role in preventing chronic diseases and addressing the challenges confronted in the region.
- 24 May 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1370595
Open AccessPersonalized nutrition: the end of the one-diet-fits-all era
Personalized Nutrition emerged as a new trend for providing nutritional and food advice based on the individual’s genetic composition, a field driven by the advancements in the multi-omic sciences throughout the last century. It intends not only to tailor the recommended daily allowances of nutrients and functional foods that a person may need but also to maintain the principles of sustainability and eco-friendliness. This principle implies the implementation of strategies within the healthcare system to advocate for the ending of the one-diet-fits-all paradigm by considering a personalized diet as an ally to prevent diet-related chronic diseases. In this Perspective, we highlight the potential benefits of such a paradigm within the region of Latin America, particularly Mexico, where the genetic admixture of the population, food biodiversity, and food culture provide unique opportunities to establish personalized nutrigenetic strategies. These strategies could play a crucial role in preventing chronic diseases and addressing the challenges confronted in the region.